Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Equity

Denali Therapeutics (DNLI) EBIT Margin (2018 - 2023)

Historic EBIT Margin for Denali Therapeutics (DNLI) over the last 6 years, with Q3 2023 value amounting to 8981.45%.

  • Denali Therapeutics' EBIT Margin fell 59613300.0% to 8981.45% in Q3 2023 from the same period last year, while for Jun 2024 it was 37938.04%, marking a year-over-year decrease of 378904900.0%. This contributed to the annual value of 59.51% for FY2023, which is 2546500.0% up from last year.
  • Latest data reveals that Denali Therapeutics reported EBIT Margin of 8981.45% as of Q3 2023, which was down 59613300.0% from 57.96% recorded in Q2 2023.
  • Denali Therapeutics' 5-year EBIT Margin high stood at 77.04% for Q4 2020, and its period low was 8981.45% during Q3 2023.
  • In the last 5 years, Denali Therapeutics' EBIT Margin had a median value of 898.9% in 2021 and averaged 1290.51%.
  • Its EBIT Margin has fluctuated over the past 5 years, first soared by 30059600bps in 2019, then tumbled by -59613300bps in 2023.
  • Over the past 5 years, Denali Therapeutics' EBIT Margin (Quarter) stood at 1236.26% in 2019, then soared by 106bps to 77.04% in 2020, then tumbled by -900bps to 616.28% in 2021, then crashed by -66bps to 1024.45% in 2022, then crashed by -777bps to 8981.45% in 2023.
  • Its EBIT Margin was 8981.45% in Q3 2023, compared to 57.96% in Q2 2023 and 343.8% in Q1 2023.